85%Confidence
0Views
FDASource
2026-03-05Date
Summary
Additional sterility issues with ketamine at Fresenius Kabi suggest systemic problems at their compounding facility. This could affect their ability to supply critical medications and damage customer trust.
Actionable: Monitor Fresenius Kabi's regulatory compliance progress and consider the impact on their overall pharmaceutical services division.
AI Confidence: 85%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productketamine HCl, 1,000 mg, 1,000 mg per 100 mL (10 mg per mL) in Sodium Chloride Injection, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 7
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now